NEW HAVEN, Conn., Feb. 8, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overview and update on the Company’s clinical programs in HIV, HCV and serious bacterial infections at the BIO CEO and Investor Conference. The Company presentation will take place on Tuesday, February 12, 2008 at 2:00 p.m. EST at the Waldorf Astoria Hotel, 301 Park Avenue, New York.
